All Updates

All Updates

icon
Filter
M&A
AbbVie acquires Celsius Therapeutics for USD 250 million to advance anti-inflammation drug development
AI Drug Discovery
Jun 27, 2024
Last week:
M&A
Nscale acquires Kontena to enhance HPC and AI infrastructure capabilities
Generative AI Infrastructure
Yesterday
Product updates
Eve Air Mobility unveils unmanned eVTOL prototype
Passenger eVTOL Aircraft
Yesterday
Product updates
Lilium advances POWER-ON, providing solutions with leading digital innovators
Passenger eVTOL Aircraft
Yesterday
Product updates
Together AI unveils new inference stack and endpoints for improved speed and efficiency
Generative AI Infrastructure
Jul 20, 2024
Industry news
New South Korean space agency provides rundown of plans
Space Travel and Exploration Tech
Jul 20, 2024
Product updates
Micron Technology introduces high-performance MRDIMMs to improve bandwidth for AI and HPC applications
Generative AI Infrastructure
Jul 19, 2024
Management news
Bionano Genomics receives Nasdaq non-compliance notice; continues trading efforts
Precision Medicine
Jul 19, 2024
Funding
GRO Biosciences raises USD 60.3 million in Series B funding to advance lead program into clinical trials and expand GRObio pipeline
Precision Medicine
Jul 19, 2024
Management news
Yooz announces new appointments in C-Suite
Business Expense Management
Jul 19, 2024
Regulation/policy
Airwallex secures license to expand retail investment offerings in Australia
FinTech Infrastructure
Jul 19, 2024
AI Drug Discovery

AI Drug Discovery

Jun 27, 2024

AbbVie acquires Celsius Therapeutics for USD 250 million to advance anti-inflammation drug development

M&A

  • AbbVie has announced the completion of the acquisition of Celsius Therapeutics. As per the agreement, AbbVie has acquired all outstanding shares of Celsius for USD 250 million, subject to certain customary adjustments.

  • Post acquisition, AbbVie plans to further advance the development of Celsius’ CEL383, , a potential first-in-class anti-TREM1 antibody that has completed a Phase I clinical trial for inflammatory bowel disease (IBD). The company states that the acquisition of Celsius and its potential drug, CEL383, is a promising step toward a new approach in IBD treatment.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.